Compare INHD & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INHD | PHGE |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | 57 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 9.2M |
| IPO Year | 2023 | N/A |
| Metric | INHD | PHGE |
|---|---|---|
| Price | $1.01 | $4.68 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 90.7K | 65.7K |
| Earning Date | 05-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,846,250.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 221.43 | N/A |
| 52 Week Low | $0.06 | $0.25 |
| 52 Week High | $15.90 | $8.50 |
| Indicator | INHD | PHGE |
|---|---|---|
| Relative Strength Index (RSI) | 39.85 | 42.86 |
| Support Level | $0.98 | $4.00 |
| Resistance Level | $1.18 | $5.99 |
| Average True Range (ATR) | 0.05 | 0.76 |
| MACD | -0.01 | -0.18 |
| Stochastic Oscillator | 2.56 | 4.50 |
Inno Holdings Inc is a building technology company with a mission to transform the construction industry with its proprietary cold-formed steel-framing technology and other innovations. It is a manufacturer of cold-formed-steel members and prefabricated homes. It offers a full range of services required to transform raw materials into precise steel framing products and prefabricated homes. The company sells these finished products either to businesses or directly to customers. The finished products and cold-formed-steel members are used in a variety of building types, including residential, commercial, industrial and infrastructure.
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).